RFA-OD-21-004: Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $200,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 5 awards worth $1.0 million in total. Applications closed on March 8, 2023.
From the official notice on Grants.gov, last changed March 10, 2021. Checked November 7, 2026.
- Award ceiling$200,000
- Total funding$1.0 million
- Expected awards5
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsNot allowed
- Funded byNIDA, NHLBI
- Median yearly award$220,375
- Typical project length3.5 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under RFA-OD-21-004 were run by National Institute on Drug Abuse (NIDA, 1 project) and National Heart Lung and Blood Institute (NHLBI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-OD-21-004 in the NIH Guide.
Key dates
| Posted | March 10, 2021 |
|---|---|
| Deadline | March 8, 2023 |
| Archived by Grants.gov | April 13, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $220,375; it allows up to $200,000 per award.
- Most of the program's money (77% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institutes (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. While other publicly available repositories would be considered, depending on analyses to be conducted, nationally representative analyses will receive priority. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set.
Funded under RFA-OD-21-004 so far
NIH funded 2 projects under RFA-OD-21-004 in fiscal 2022 to 2024, at 2 institutions. The median yearly award was $220,375.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Network-based analysis of disease-associated epigenetic changes in youth electronic cigarette users | University of Southern California | 2024 | $207,500 |
| Airway Biomarker Based Assessment of Combusted to Non-Combusted Tobacco Use Transition Effects | Univ of North Carolina Chapel Hill | 2023 | $233,250 |
Who has won Family Smoking Prevention and Tobacco Control Act Regulatory Research grants before
From fiscal 2021 to 2025, Family Smoking Prevention and Tobacco Control Act Regulatory Research (93.077) awarded $313 million across 176 grant awards, an average of $1.8 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 10 | $28.4 million |
| University of Southern California | California | 6 | $23.0 million |
| University of North Carolina at Chapel Hill | North Carolina | 11 | $20.9 million |
| Regents of the University of Michigan | Michigan | 3 | $20.3 million |
| The Ohio State University | Ohio | 9 | $18.9 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-OD-21-004 still open?
No. It closed on March 8, 2023.
Who can apply for Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)?
Closed March 8, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $200,000 each. About $1.0 million in total across about 5 awards.
Who has been funded under RFA-OD-21-004?
NIH RePORTER lists 2 projects funded under RFA-OD-21-004 in fiscal 2022 to 2024, at 2 institutions. The most were at University of Southern California, Univ of North Carolina Chapel Hill.
Who has won Family Smoking Prevention and Tobacco Control Act Regulatory Research grants before?
The largest recipients over five fiscal years were Yale Univ, University of Southern California, University of North Carolina at Chapel Hill. The program made 176 awards worth $313 million in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)